Literature DB >> 16303106

New therapies and preventive strategies to treat and minimize damage in lupus.

Henda Bouali1, Gary Gilkeson.   

Abstract

Systemic lupus erythematosus is a complex disease characterized by a loss of immune tolerance leading to autoantibody production, immune complex deposition in target organs, and resultant tissue damage. There are currently only three medications approved for the treatment of lupus; hydroxychloroquine, aspirin, and prednisone. This limited spectrum of medications is contrasted by the dozen clinical trials in lupus underway or planned for the next 2 years. These new therapeutic agents hold promise for being more effective with fewer side effects than the current available agents. Increased awareness of co-morbid diseases in lupus is also leading to new approaches for the prevention of "disease damage" in lupus.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16303106     DOI： 10.1007/s11926-005-0052-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  30 in total

1.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

Authors:  P P Sfikakis; J N Boletis; S Lionaki; V Vigklis; K G Fragiadaki; A Iniotaki; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  2005-02

3.  Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline.

Authors:  R Segal; M Dayan; H Zinger; E Mozes
Journal:  Lupus       Date:  2001       Impact factor: 2.911

4.  Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients.

Authors:  Ann E Traynor; Walter G Barr; Robert M Rosa; Julianne Rodriguez; Yu Oyama; Steven Baker; Mary Brush; Richard K Burt
Journal:  Arthritis Rheum       Date:  2002-11

5.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Authors:  Joel M Kremer; Maxime Dougados; Paul Emery; Patrick Durez; Jean Sibilia; William Shergy; Serge Steinfeld; Elizabeth Tindall; Jean-Claude Becker; Tracy Li; Isaac F Nuamah; Richard Aranda; Larry W Moreland
Journal:  Arthritis Rheum       Date:  2005-08

6.  Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

Authors:  L Llorente; Y Richaud-Patin; C García-Padilla; E Claret; J Jakez-Ocampo; M H Cardiel; J Alcocer-Varela; L Grangeot-Keros; D Alarcón-Segovia; J Wijdenes; P Galanaud; D Emilie
Journal:  Arthritis Rheum       Date:  2000-08

Review 7.  The emerging role of interferon in human systemic lupus erythematosus.

Authors:  Emily C Baechler; Peter K Gregersen; Timothy W Behrens
Journal:  Curr Opin Immunol       Date:  2004-12       Impact factor: 7.486

8.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Authors:  Martin Aringer; Winfried B Graninger; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2004-10

9.  Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

Authors:  K M Uramoto; C J Michet; J Thumboo; J Sunku; W M O'Fallon; S E Gabriel
Journal:  Arthritis Rheum       Date:  1999-01

10.  Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood.

Authors:  E Hagiwara; M F Gourley; S Lee; D K Klinman
Journal:  Arthritis Rheum       Date:  1996-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.